September 17, 2012 -- Almac has today announced the launch of a new reagent offering based on the provision of homogeneous full length histones with defined patterns of modification. The histone reagents will prove a highly valuable tool for researchers seeking to prosecute key drug targets in the field of epigenetics.

Almac’s unique array of platform technologies for the chemical synthesis of proteins, enable the provision of pure full-length natural histones containing a wide variety of post-translational modifications at any specified site(s) within the protein. The reagents are set to be offered through a catalogue of modified histones and additionally as a custom synthesis service to meet bespoke customer demands. Almac believes this will provide the epigenetic research community with a unique source of enabling research tools. The modified histone reagent provision complements Almac’s growing range of FLEXYTE® FLT assays for epigenetic targets.

‘This is a first class example of how Almac can harness its unique protein synthesis capability to provide a much needed source of tools to the epigenetic research field. I am delighted that we are able to offer such capabilities.’ commented Dr Charles Shields, Vice President of Peptide and Protein Technologies at Almac.

About Almac

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

For more information about the Almac Group, please visit www.almacgroup.com or e-mail info@almacgroup.